Pharmacogenomics and genetic testing

Since the sequencing of the human genome, the development of genetic tests has broadened the horizon for pharmacogenomics. The economic impact on traditional pharmaceutical markets is expected to be considerable, suggesting the emergence of new types of blockbusters, new approaches for valorization and public healthcare coverage. The economic model for personalized medicine, adapted to the genetic profile of a group of patients, should enable the marketing of targeted drugs, with significantly improved safety/efficacy ratios compared with reference treatments. The Chair studies the economic viability of such a model for industrial players and its impact for health authorities. A detailed analysis of filed patents as well as ongoing clinical trials involving gene markers suggests the emergence of a new market dynamic. The Chair also studies marketing implications linked to the online commercialization of genetic tests, the digitalization of personal medical records, as well as the use of this data by insurance companies or employers.